Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020;22(8):E743-750. doi:
10.1001/amajethics.2020.743.
As larger organizations become more influential in the health care sector, the Code can help physicians navigate those organizations’ influence on their practices.
AMA J Ethics. 2020;22(3):E217-220. doi:
10.1001/amajethics.2020.217.
Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.
AMA J Ethics. 2020;22(3):E221-231. doi:
10.1001/amajethics.2020.221.
Corporatization in health care has complicated clinicians’ and organizations’ efforts to balance interests of individual patients against an organization’s bottom line.
AMA J Ethics. 2020;22(3):E187-192. doi:
10.1001/amajethics.2020.187.
Jonathan Alhalel, Nicolás Francone, Sharon Post, Catherine A. O’Brian, PhD, and Melissa A. Simon, MD, MPH
Underrepresentation of individuals with limited English proficiency who speak Spanish is ongoing in phase 3 biomedical clinical trials and exacerbates health inequity.
AMA J Ethics. 2022;24(4):E319-325. doi:
10.1001/amajethics.2022.319.
Wandy D. Hernandez-Gordon, CD(DONA), BDT(DONA), CLC, CCE(ACBE)
CHWs’ work underscores need for clinicians and organizations to respond to deeply entrenched, long-standing patterns of oppression in ways that draw upon lived experience.
AMA J Ethics. 2022;24(4):E333-339. doi:
10.1001/amajethics.2022.333.